3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
10
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
12
Neuroendocrine Tumors
5
Neoplasm Metastasis
5
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
3
Adenoma, Islet Cell
3
Recurrence
2
Meningioma
2
Glioblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Carcinoma, Hepatocellular
2
Carcinoid Tumor
2
von Hippel-Lindau Disease
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Thymus Neoplasms
1
Sarcoma
1
Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Lymphangioleiomyomatosis
1
Locally Advanced Thyroid Gland Carcinoma
1
Kidney Neoplasms
1
HR+/HER2- Advanced Breast Cancer
1
Glioma
1
Gastroenteropancreatic Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gallbladder Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Interventions
Bevacizumab
76
Fluorouracil
56
Cetuximab
47
Leucovorin
44
Oxaliplatin
43
pembrolizumab
35
Irinotecan
34
Folfox protocol
24
Capecitabine
24
HMPL-013
22
Specimen Handling
18
trifluridine tipiracil drug combination
16
Nivolumab
15
Blood Specimen Collection
15
Panitumumab
14
regorafenib
13
Magnetic Resonance Spectroscopy
13
Trifluridine
12
Standard of Care
12
Gemcitabine
12
Biopsy
12
Cisplatin
11
sintilimab
10
Interviews as Topic
10
IFL protocol
10
Drug Therapy
10
Carboplatin
9
tislelizumab
8
Trastuzumab
8
Cyclophosphamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colorectal Neoplasms
×
Everolimus
×
Clear all
NCT05725200
2023-02-21
EVIDENT
Oslo University Hospital
Phase 2
Recruiting
40 enrolled